What Happened
- Finance Minister Nirmala Sitharaman announced the Biopharma SHAKTI scheme in Union Budget 2026-27, with an outlay of Rs 10,000 crore over five years.
- SHAKTI stands for: BioPharma Strategy for Health Advancement through Knowledge, Technology and Innovation.
- The scheme targets India's biologics and biosimilars sector — pharmaceuticals derived from living organisms rather than chemical synthesis — with the goal of capturing 5% of the global biopharmaceutical market.
- Key components include: establishing three new National Institutes of Pharmaceutical Education and Research (NIPERs), upgrading seven existing NIPERs, creating 1,000+ accredited clinical trial sites nationwide, and strengthening the Central Drugs Standard Control Organisation (CDSCO) with a dedicated scientific review cadre.
- The scheme is part of a broader Budget 2026-27 health sector push, with a total healthcare outlay of Rs 1.05 lakh crore.
Static Topic Bridges
Biologics and Biosimilars: The New Frontier of Pharmaceuticals
Traditional pharmaceuticals (small-molecule drugs) are synthesised through chemical processes — aspirin, paracetamol, antibiotics. Biologics, in contrast, are large, complex molecules derived from living cells (bacteria, yeast, mammalian cells) through biotechnology — these include vaccines, monoclonal antibodies, insulin, and gene therapies. Biosimilars are the generic equivalents of biologics: once the original biologic's patent expires, other manufacturers can produce a "highly similar" version (a biosimilar) that has been shown to have no clinically meaningful differences in safety, purity, and potency. Biologics are the fastest-growing segment of the global pharmaceutical market, accounting for ~35% of all drug sales and a disproportionate share of the top-selling drugs globally.
- Monoclonal antibodies (mAbs): largest class of biologics; used for cancer (Herceptin, Keytruda), autoimmune diseases (Humira), and increasingly infectious diseases.
- Global biologics market: approximately $400 billion in 2024; projected to reach $800 billion by 2030.
- India's existing biosimilar strength: India already produces several WHO-prequalified biosimilars (Biocon's Herceptin biosimilar, insugen); but remains a fraction of the global market.
- Key difference from generic small-molecule drugs: biosimilars require sophisticated manufacturing (bioreactors, cold-chain), expensive clinical trials, and greater regulatory scrutiny — higher barriers than generics.
- India's biosimilar market size: ~$1 billion in 2024, but growing at 25%+ CAGR.
Connection to this news: Biopharma SHAKTI is designed to move India from its established position as the "pharmacy of the world" for generic small-molecule drugs into the higher-value biologics and biosimilars space — where the global pharmaceutical market is growing fastest.
India's Pharmaceutical Sector: Strength, Gap, and Strategic Ambition
India is the world's third-largest pharmaceutical industry by volume and the largest supplier of generic medicines globally, supplying ~20% of the world's generic medicines by volume and 50% of Africa's vaccines. However, India's pharma strength is primarily in generics (off-patent small-molecule drugs), not in innovative biologics or novel drug discovery. This creates a value-capture gap: India manufactures and exports at low margins while innovator companies (primarily US, EU, Japanese firms) capture the high-margin biologics revenue. The Biopharma SHAKTI scheme is explicitly designed to close this gap by building the full biologics ecosystem — R&D, manufacturing, clinical trials, and regulatory infrastructure.
- India's pharma exports: ~$27 billion in FY 2024-25; a top-10 global pharma exporter.
- India supplies 50%+ of global vaccine demand (Serum Institute of India is the world's largest vaccine manufacturer by volume).
- PLI for Pharmaceuticals: Rs 15,000 crore scheme covering bulk drugs (APIs) and medical devices — biosimilars are now added as a priority.
- National Pharmaceutical Pricing Authority (NPPA): regulates drug prices under DPCO (Drug Price Control Order) — important for ensuring affordable biologics for domestic patients.
- CDSCO (Central Drugs Standard Control Organisation): India's drug regulatory authority under the Drugs and Cosmetics Act, 1940; equivalent to USFDA.
- India has the world's highest number of USFDA-approved manufacturing plants outside the US — reflecting existing GMP compliance capability.
Connection to this news: The CDSCO strengthening component of Biopharma SHAKTI is critical — global pharma companies will only invest in Indian biologics manufacturing if they trust that Indian regulatory approvals are recognised internationally. A stronger CDSCO accelerates this trust.
Clinical Trials Infrastructure: India's Underutilised Advantage
Clinical trials are the process of testing drugs, vaccines, and medical devices on human subjects in controlled settings before regulatory approval. India has significant natural advantages for clinical trials: large, genetically diverse patient population; high disease burden (allowing large trial cohorts); English-speaking medical community; lower costs (~50–60% cheaper than the US/EU); and a growing base of trained clinical investigators. However, India's share of global clinical trial activity remains below its potential — hampered by regulatory complexity, infrastructure deficits, and the aftermath of a 2012-13 moratorium on new trials following adverse event controversies. The Biopharma SHAKTI commitment to establish 1,000+ accredited clinical trial sites is a major step toward rebuilding and expanding India's clinical research ecosystem.
- Clinical trial phases: Phase I (safety, small healthy volunteer group) → Phase II (efficacy, larger patient group) → Phase III (large-scale efficacy and safety, thousands of patients) → Phase IV (post-marketing surveillance).
- India's clinical trial regulatory framework: New Drugs and Clinical Trials Rules, 2019 (simplified process vs. 2013 rules).
- India's share of global clinical trials: ~5–6% as of 2024 (target: 10%+ by 2030 under Biopharma SHAKTI).
- NIPERs: National Institutes of Pharmaceutical Education and Research — established under the NIPER Act, 1998; existing seven located in Ahmedabad, Hajipur, Hyderabad, Kolkata, Lucknow, Mohali, Raebareli.
- Three new NIPERs: to be announced in locations with existing pharma clusters or medical universities.
- Global clinical trial market: ~$72 billion in 2024; India's addressable share is several billion dollars.
Connection to this news: The 1,000+ accredited clinical trial sites target under Biopharma SHAKTI would transform India's clinical research capacity — enabling Indian biologics companies to run pivotal trials domestically rather than outsourcing them to the US/EU, reducing both cost and time to market.
Key Facts & Data
- Biopharma SHAKTI: Rs 10,000 crore outlay over 5 years (Budget 2026-27).
- SHAKTI: BioPharma Strategy for Health Advancement through Knowledge, Technology and Innovation.
- Target: Capture 5% of global biopharmaceutical market.
- Global biologics market: ~$400 billion (2024), projected $800 billion by 2030.
- India's biosimilar market: ~$1 billion (2024), growing at 25%+ CAGR.
- NIPERs: 3 new to be established; 7 existing to be upgraded.
- Clinical trial sites: 1,000+ accredited sites to be created nationwide.
- CDSCO: India's drug regulator; to be strengthened with dedicated scientific review cadre under SHAKTI.
- India pharma exports: ~$27 billion (FY 2024-25); third-largest pharma industry by volume globally.
- India's USFDA-approved plants: highest outside the US globally.
- NIPERs established under: NIPER Act, 1998.
- Clinical trial framework: New Drugs and Clinical Trials Rules, 2019.
- Total healthcare Budget 2026-27: Rs 1.05 lakh crore.